Promising results were obtained in clinical trials evaluating the efficacy of polyclonal CTLs enriched for the LMP1 and LMP2 antigens, where durable clinical responses without significant toxicity were observed in heavily pre-treated patients with EBV-associated lymphoma (117). This evidence concerns the gene PSMB9 and lymphoma.